Literature DB >> 1399416

Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy.

T Moritera1, Y Ogura, N Yoshimura, Y Honda, R Wada, S H Hyon, Y Ikada.   

Abstract

The use of biodegradable polymer microspheres containing adriamycin for the treatment of proliferative vitreoretinopathy (PVR) in an experimental rabbit model was investigated. A single injection of microspheres containing 10 micrograms of adriamycin effectively decreased traction retinal detachment to 10% (n = 10), whereas 50% of eyes injected with blank microspheres (n = 10) developed retinal detachment (P < 0.05). A single injection of microspheres, containing 3 micrograms of adriamycin, did not suppress retinal detachment. Electroretinographic and histologic studies confirmed that the 10 micrograms injection of adriamycin in microspheres was not toxic to the retina, although the injection of the same amount of free adriamycin caused retinal necrosis and detachment. Thus, microspheres containing adriamycin hold promise as a new treatment modality for PVR.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399416

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  15 in total

Review 1.  Biodegradable implants for sustained drug release in the eye.

Authors:  Susan S Lee; Patrick Hughes; Aron D Ross; Michael R Robinson
Journal:  Pharm Res       Date:  2010-06-10       Impact factor: 4.200

2.  Comparative transcriptomic analysis reveals adriamycin-induced apoptosis via p53 signaling pathway in retinal pigment epithelial cells.

Authors:  Yu-Chen Lin; Ze-Ren Shen; Xiao-Hui Song; Xin Liu; Ke Yao
Journal:  J Zhejiang Univ Sci B       Date:  2018 Dec.       Impact factor: 3.066

Review 3.  New techniques for drug delivery to the posterior eye segment.

Authors:  Esther Eljarrat-Binstock; Jacob Pe'er; Abraham J Domb
Journal:  Pharm Res       Date:  2010-02-13       Impact factor: 4.200

Review 4.  Polymeric vectors for ocular gene delivery.

Authors:  Viral Tamboli; Gyan P Mishra; Ashim K Mitrat
Journal:  Ther Deliv       Date:  2011-04

Review 5.  Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.

Authors:  I Bravo-Osuna; V Andrés-Guerrero; P Pastoriza Abal; I T Molina-Martínez; R Herrero-Vanrell
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

6.  Drug delivery to the posterior segment of the eye for pharmacologic therapy.

Authors:  Shalin S Shah; Lori Vidal Denham; Jasmine R Elison; Partha S Bhattacharjee; Christian Clement; Tashfin Huq; James M Hill
Journal:  Expert Rev Ophthalmol       Date:  2010-02-01

Review 7.  Intraocular sustained-release delivery systems for triamcinolone acetonide.

Authors:  Saffar Mansoor; Baruch D Kuppermann; M Cristina Kenney
Journal:  Pharm Res       Date:  2009-01-28       Impact factor: 4.200

Review 8.  Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications.

Authors:  Blake A Booth; Lori Vidal Denham; Saadallah Bouhanik; Jean T Jacob; James M Hill
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 9.  Biodegradable intraocular therapies for retinal disorders: progress to date.

Authors:  Noriyuki Kuno; Shinobu Fujii
Journal:  Drugs Aging       Date:  2010-02-01       Impact factor: 3.923

10.  Studies on Indomethacin Intraocular Implants Using Different in vitro Release Methods.

Authors:  J Balasubramaniam; A Srinatha; J K Pandit
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.